Bioceltix S.A. Logo

Bioceltix S.A.

ISIN: PLBCLTX00019 | Ticker: BCX | LEI: 259400QZD5JYK8SLZU51
Sector: Health CareSub-Industry: Biotechnology
Country: Poland

About Bioceltix S.A.

Company Description

Bioceltix is a team of experts working on innovative therapies for veterinary use. We work on biopharmaceuticals that harness the immunomodulatory properties of mesenchymal stem cells. We develop them following the highest quality and safety standards. We possess cutting-edge research and production facilities, cooperate with ambitious scientists, and operate under a well-developed business model. Our goal is to market new, effective solutions in the field of veterinary medicine.

The safety and efficacy of Bioceltix products will also be verified through field clinical trials carried out in accordance with Good Clinical Practice (GCP). The independent trials will be conducted in leading veterinary centres, under the supervision of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL).

Year founded

2018

Served area

Worldwide

Headquarters

Bierutowska 57-59/Bud.Iii, 51-317 Wrocław – Poland

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

PLBCLTX00019

LEI

259400QZD5JYK8SLZU51

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Warsaw Stock Exchange

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.